Merck announced new clinical data from the company’s cardio-pulmonary pipeline will be presented at the American College of Cardiology’s Annual Scientific Session and Expo (ACC.26) in New Orleans, La., from 28-30 March, 2026. The results shared will highlight Merck’s unwavering commitment to advancing innovative research in hypercholesterolemia and in the syndrome of combined post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction (CpcPH-HFpEF) to help address the significant burden of these diseases.

Key data being shared include two late-breaking presentations: positive results from the phase-III CORALreef AddOn trial evaluating the efficacy and safety of enlicitide, an investigational, once-daily oral Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor versus ezetimibe, versus bempedoic acid and versus ezetimibe and bempedoic acid in adults with hypercholesterolemia who are treated with a statin; and positive results from the phase-II CADENCE trial evaluating WINREVAIR (sotatercept-csrk) in adults with CpcPH-HFpEF.

“The data planned for presentation at ACC will underscore the strength and momentum of Merck’s cardio-pulmonary pipeline as we work to advance research that helps address the CV epidemic impacting millions with atherosclerosis, as well as CpcPH-HFpEF, a distinct syndrome with limited treatment options. Building on our history of bringing forward innovative therapies in heart and lung disease, we are proud to share research at ACC.26 that improves our understanding of these serious diseases and has the potential to help patients around the world,” said Dr Joerg Koglin, Senior Vice President, Head – General and Specialty Medicine, Global Clinical Development, Merck Research Laboratories.